Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years

Inclusion Criteria: * Healthy subjects aged 2\~3 months (minimum 6 weeks old) and 7 months old\~17 years old, and the guardian of the subject can provide valid identification of the subject and the guardian of the subject. * Subjects and/or their guardians voluntarily consent to the subjects to participate in this study and sign the informed consent form. * Subjects and/or their guardians have the ability to understand (non-illiterate) study procedures. * Female subjects and male subjects of childbearing age agree to use effective contraceptive measures within 6 months from the start of the study to the date of immunization. * Those who have completed the full course of primary immunization in accordance with the requirements of this clinical trial, and the age before the booster immunization is 12\~15 months old, (the interval between the booster immunization time and the last dose of primary immunization is at least 2 months). * In the opinion of the investigator, the subject's guardian can comply with all the requirements of this clinical trial protocol during the booster phase of the subject. Exclusion Criteria: * Individuals who have previously received any type of pneumococcal vaccine or have a history of invasive disease caused by Streptococcus pneumoniae (confirmed by clinical, serological, or microbiological methods). * Abnormal results from physical examinations or laboratory tests that are deemed clinically significant by a clinician. * Individuals suspected or …